Resources

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

September 1, 2021 | Poster
Combination treatment with radiotherapy and oncolytic reovirus generates CD8+ T cell infiltration in primary and abscopal tumours in an organoid model of basal-like breast cancer
Singer R et al. Previously presented at The International Conference on Immunotherapy Radiotherapy Combinations
June 1, 2021 | Poster
Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma
Mahalingam D et al. Previously presented at the 2021 ASCO Annual Meeting
April 10, 2021 | Poster
Talazoparib interacts with oncolytic reovirus to enhance death-inducing signaling complex (DISC)-mediated apoptosis and immune response
Kyula J et al. In: AACR Virtual Annual Meeting 2021; 2021 Apr 10-15; Virtual. AACR; 2021. Abstract 1932
April 10, 2021 | Poster
A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (AWARE-1)
Manso L et al. In: AACR Virtual Annual Meeting 2021; 2021 Apr 10-15; Virtual. AACR; 2021. Abstract CT191
April 10, 2021 | Poster
Mechanisms of therapeutic synergy between pattern recognition response agonists and CDK4 inhibitors
Roulstone V et al. In: AACR Virtual Annual Meeting 2021; 2021 Apr 10-15; Virtual. AACR; 2021. Abstract 1960
February 1, 2021 | Poster
Combination Therapy with Oncolytic Viruses and CAR T Cells
Kottke et al, Previously presented at CAR-TCR Summit Europe 2021
December 9, 2020 | Poster
A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)
Manso et al, Previously presented at the 2020 Virtual San Antonio Breast Cancer Symposium® - 43rd Annual Meeting;  San Antonio, TX, USA; December 9-11, 2020
December 9, 2020 | Poster
BRACELET-1 (PrE0113): A study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel
Miller et al, Previously presented at the 2020 Virtual San Antonio Breast Cancer Symposium® - 43rd Annual Meeting;  San Antonio, TX, USA; December 9-11, 2020

Expanded Access

Oncolytics believes that participating in clinical trials is the best way for patients to access pelareorep. We are not currently able to fulfill expanded access requests at this time.

Information on many of Oncolytics clinical trials can be found at Home – ClinicalTrials.gov. If a treating physician would like additional information, the physician should directly contact Oncolytics at info@oncolytics.ca.

Information on many of Oncolytics clinical trials can be found at Home – ClinicalTrials.gov. If a treating doctor would like additional information, the doctor should formally contact Oncolytics at info@oncolytics.ca.

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch